Septerna Inc (SEPN)

Apr 14, 2026

Septerna (SEPN) price target increased by 34.39% to 46.41 - MSN

Apr 14, 2026

Apr 14, 2026

SEPN Reiterated by HC Wainwright & Co. -- Price Target Maintained at $40 - GuruFocus

Apr 14, 2026

Apr 14, 2026

Septerna: Advancing GPCR Pipeline and Strategic Partnerships Support Buy Rating and $40 Price Target - TipRanks

Apr 14, 2026

Apr 14, 2026

Is Septerna (SEPN) Using Its First PTH1R Trial To Redefine Its GPCR Strategy? - Sahm

Apr 14, 2026

Apr 14, 2026

H.C. Wainwright reiterates Septerna stock rating on trial start By Investing.com - Investing.com South Africa

Apr 14, 2026

Apr 13, 2026

Septerna Announces Initiation of Phase 1 Clinical Trial of SEP-479, an Oral Small Molecule PTH1R Agonist for the Treatment of Hypoparathyroidism - Bitget

Apr 13, 2026

Apr 13, 2026

SEPTERNA INCPHASE 1 TRIAL DATA EXPECTED IN LATE 2026 OR EARLY 2027 - Moomoo

Apr 13, 2026

Apr 13, 2026

Septerna doses first patient in SEP-479 hypoparathyroidism trial By Investing.com - Investing.com Australia

Apr 13, 2026

Apr 13, 2026

Insider Buy: Is Septerna Inc part of any ETF2026 Sector Review & Risk Controlled Stock Alerts - baoquankhu1.vn

Apr 13, 2026

Apr 13, 2026

Septerna (SEPN) Initiates Phase 1 Trial for Hypoparathyroidism T - GuruFocus

Apr 13, 2026

Apr 13, 2026

Movement Recap: Will Septerna Inc benefit from current market trendsWeekly Loss Report & Accurate Buy Signal Notifications - baoquankhu1.vn

Apr 13, 2026

Apr 13, 2026

Septerna Begins Phase 1 Clinical Trial of SEP-479, an Oral PTH1R Agonist, for Hypoparathyroidism Treatment – Data Expected Late 2026/Early 2027 1 - Minichart

Apr 13, 2026

Apr 13, 2026

Septerna Begins Phase 1 Trial of Oral SEP-479 - TipRanks

Apr 13, 2026

Apr 13, 2026

Septerna doses first patient in SEP-479 hypoparathyroidism trial - Investing.com

Apr 13, 2026

Apr 13, 2026

Septerna begins Phase 1 trial of oral PTH1R agonist SEP-479; Phase 1 data expected late 2026–early 2027 - TradingView — Track All Markets

Apr 13, 2026

Apr 13, 2026

Septerna (Nasdaq: SEPN) begins Phase 1 trial of SEP-479 for hypoparathyroidism - Stock Titan

Apr 13, 2026

Apr 13, 2026

Septerna starts human testing of an oral drug for a lifelong disorder - Stock Titan

Apr 13, 2026

Apr 13, 2026

Buyout Rumor: How does Septerna Inc correlate with NasdaqEarnings Beat & Real-Time Volume Analysis - baoquankhu1.vn

Apr 13, 2026

Apr 09, 2026

FOMO Trade: Is Septerna Inc part of any ETF2026 Technical Overview & High Accuracy Trade Signal Alerts - baoquankhu1.vn

Apr 09, 2026

Apr 09, 2026

Will Septerna Inc benefit from current market trends2026 Price Momentum & Weekly High Conviction Ideas - baoquankhu1.vn

Apr 09, 2026

Apr 08, 2026

SEPN: Septerna, Inc.Detailed Earnings Estimates - Zacks Investment Research

Apr 08, 2026

Mar 28, 2026

Septerna tops Q4 loss expectations as collaboration revenue lifts results - MSN

Mar 28, 2026

Mar 25, 2026

Septerna, Inc. (NASDAQ:SEPN) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat

Mar 25, 2026

Mar 24, 2026

J.P. Morgan Maintains Septerna(SEPN.US) With Buy Rating, Announces Target Price $38 - Moomoo

Mar 24, 2026

Mar 24, 2026

Septerna (NASDAQ:SEPN) Given New $38.00 Price Target at JPMorgan Chase & Co. - marketbeat.com

Mar 24, 2026

Mar 24, 2026

JP Morgan Raises Price Target for Septerna (SEPN) to $38 | SEPN Stock News - GuruFocus

Mar 24, 2026

Mar 24, 2026

Septerna price target raised to $38 from $34 at JPMorgan - TipRanks

Mar 24, 2026

Mar 23, 2026

Should Septerna’s New ATM and Shelf Offering Strategy Require Action From Septerna (SEPN) Investors? - simplywall.st

Mar 23, 2026

Mar 21, 2026

Big Picture: How volatile is Septerna Inc stock2026 WrapUp & Free Low Drawdown Momentum Trade Ideas - baoquankhu1.vn

Mar 21, 2026

Mar 19, 2026

Septerna (SEPN) Expected to Announce Earnings on Thursday - MarketBeat

Mar 19, 2026

Mar 17, 2026

Layoff Watch: Will Septerna Inc outperform the market in YEARTrade Entry Report & Long-Term Safe Investment Ideas - baoquankhu1.vn

Mar 17, 2026

Mar 16, 2026

Septerna (SEPN) Is Down 13.5% After Launching US$150 Million ATM Equity Program and Filing Shelves - simplywall.st

Mar 16, 2026

Mar 15, 2026

Checkpoint Capital L.P. Trims Stock Position in Septerna, Inc. $SEPN - MarketBeat

Mar 15, 2026

Mar 14, 2026

Avoro Capital Advisors LLC Grows Stock Holdings in Septerna, Inc. $SEPN - MarketBeat

Mar 14, 2026

Mar 14, 2026

Septerna (NASDAQ:SEPN) Rating Lowered to "Hold" at Wall Street Zen - MarketBeat

Mar 14, 2026

Mar 13, 2026

HC Wainwright Has Negative Outlook for Septerna Q1 Earnings - MarketBeat

Mar 13, 2026

Mar 12, 2026

What is HC Wainwright's Forecast for Septerna Q1 Earnings? - MarketBeat

Mar 12, 2026

Mar 12, 2026

Analysts Conflicted on These Technology Names: Fortinet (FTNT), Septerna, Inc. (SEPN) and Oracle (ORCL) - The Globe and Mail

Mar 12, 2026

Mar 11, 2026

Truist Financial Forecasts Strong Price Appreciation for Septerna (NASDAQ:SEPN) Stock - MarketBeat

Mar 11, 2026

Mar 11, 2026

Septerna (SEPN) Q4 Loss Despite Revenue Surge Reinforces Bearish Profitability Narrative - simplywall.st

Mar 11, 2026

Mar 11, 2026

Wells Fargo Reaffirms Their Buy Rating on Septerna, Inc. (SEPN) - The Globe and Mail

Mar 11, 2026

Mar 11, 2026

Truist Lifts Price Target on Septerna to $35 From $34, Keeps Buy Rating - marketscreener.com

Mar 11, 2026

Mar 11, 2026

Cantor Fitzgerald Maintains Overweight on Septerna, Inc. (SEPN) March 2026 - Meyka

Mar 11, 2026

Mar 10, 2026

Truist raises Septerna stock price target to $35 on trial progress - Investing.com

Mar 10, 2026

Mar 10, 2026

Cantor Fitzgerald reiterates Septerna stock rating on platform value By Investing.com - Investing.com Australia

Mar 10, 2026

Mar 10, 2026

Cantor Fitzgerald reiterates Septerna stock rating on platform value - Investing.com

Mar 10, 2026